A CAR T Revolution: Allogene is Bringing Lifesaving Cancer Treatment to More Patients

Next Question with Katie Couric

CAR T therapy has delivered remarkable results for people with certain blood cancers—sometimes sending aggressive disease into deep remission after a single infusion. But today, only about 20% of eligible patients can actually get it. In this episode, sponsored by our partners at Allogene Therapeutics, Katie sits down with Dr. Zachary Roberts to unpack why access remains so limited and how new allogeneic (or “off-the-shelf”) CAR T therapies could be a turning point. They discuss how using healthy donor T-cells, rather than a patient's own, may help bypass manufacturing hurdles and bring advanced treatment to more oncologists, more hospitals, and more communities. To learn more, visit Alpha3trial.com. #AllogenePartner

Hosted on Acast. See acast.com/privacy for more information.

More description
CAR T therapy has delivered remarkable results for people with certain blood cancers—sometimes sending aggressive disease into deep remission after a single infusion. But today, only about 20% of eligible patients can actually get it. In this episode, sponsored by our partners at Allogene Therapeutics, Katie sits down with Dr. Zachary Roberts to unpack why access remains so limited and how new allogeneic (or “off-the-shelf”) CAR T therapies could be a turning point. They discuss how using healthy donor T-cells, rather than a patient's own, may help bypass manufacturing hurdles and bring advanced treatment to more oncologists, more hospitals, and more communities. To learn more, visit Alpha3trial.com. #AllogenePartner

Hosted on Acast. See acast.com/privacy for more information.

2025-11-24 53 min Transcript
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

Open the Transcript tab to load the transcript.

Chapters

No chapters available.